在加拿大对无控高血压的射频损伤的成本效益分析
Philip A McFarlane1, Mina Madan2,3, Anne M Ryschon4
1Division of Nephrology, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.
Journal of medical economics
|December 11, 2024
概括
射频损伤 (RF RDN) 是加拿大无控高血压的经济有效治疗方法. 这种疗法减少了临床事件,并改善了医疗保健系统内的质量调整寿命年 (QALYs).
科学领域:
- 心血管医学 心血管医学
- 卫生经济学 卫生经济学
- 干预心脏病学 干预心脏病学
背景情况:
- 失控的高血压带来了严重的健康风险和经济负担.
- 导管式射频损伤 (RF RDN) 是一种新兴的干预治疗选择.
- 评估RF RDN的成本效益对于加拿大的医疗保健资源分配至关重要.
研究的目的:
- 评估基于导管的射频脏缩 (RF RDN) 对不受控制的高血压的终身成本效益.
- 将RF RDN与加拿大医疗保健系统内的标准护理进行比较.
- 确定RF RDN是否符合成本效益的共同支付意愿门.
主要方法:
- 采用决策分析的马尔科夫模型来模拟生命周期内的健康事件,成本和质量调整寿命年 (QALYs).
- 模拟了七种健康状况:高血压,中风,心肌梗塞 (MI),冠状动脉疾病,心力衰竭 (HF),末期脏疾病 (ESRD) 和死亡.
- 过渡概率来自多变量风险方程和高血压试验的元回归,治疗效果基于SPYRAL HTN-ON MED试验.
主要成果:
- 在10年内,RF RDN显示了临床事件的减少,包括中风 (0.80相对风险),MI (0.88相对风险) 和HF (0.72相对风险).
- 基准案例分析预计RF RDN将以6,031美元的增量成本增加0.51个QALY,从而获得每QALY11,809美元的增量成本效益比率 (ICER).
- 敏感性分析证实了这些发现的稳定性,ICER的95%置信区间为每QALY获得的4,489美元至22,587美元.
结论:
- 射频损伤 (RF RDN) 预计将成为加拿大无控高血压的经济有效的治疗策略.
- 该疗法可显著减少临床事件并改善患者的治疗结果.
- 这些发现支持将RF RDN整合到加拿大医疗保健系统中,用于管理不受控制的高血压.
关键词:
在C5050中,你会发现C50是什么?加拿大 加拿大 加拿大 加拿大 加拿大D61 D61 D61 D61 这是一个很好的例子.在高血压的高血压.一千一百零一年 一百一十年分析成本效益分析.无线电频率剥离方式脏变质是指脏的变质.更多相关视频
11:08Novel Approach for Simultaneous Recording of Renal Sympathetic Nerve Activity and Blood Pressure with Intravenous Infusion in Conscious, Unrestrained Mice.
Published on: February 14, 2018
10.1K
08:33Author Spotlight: Methodologies and Advancements of Chronic Pain Management Research
Published on: January 5, 2024
1.1K
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
385
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
385
01:25Antihypertensive Drugs: Direct Renin Inhibitors
490
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
490
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
455
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
455